Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-1492 in Relapsed or Refractory Multiple Myeloma
NCT05007418Phase 1Recruiting
- Sponsor
- Sorrento Therapeutics
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of STI-1492 in multiple myeloma (MM) (4 cohorts), sponsored by Sorrento Therapeutics. Primary endpoint: Safety of STI-1492 at 54 months. Started Oct 2022; status: recruiting.
02
Drugs
STI-1492
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05007418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007418.